Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

As a result, since the start of the year, two formerly down-and-out stocks in these industries are outperforming the S&P 500.

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

This little-known biotech could have a big hit on its hands with VK2735, a GLP-1 weight loss drug candidate.

A Relative Strength Rating upgrade for Phathom Pharmaceuticals shows improving technical performance.

XBI has nearly 50 points of upside to reach its previous all-time high, and 2026 biotech industry conditions may help it get ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector's two major indexes - the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) - ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

ClearBridge Investments, a global equity manager, recently published first-quarter 2026 commentary for its “Small Cap Growth Strategy”. A copy of the letter can be downloaded here. The beginning of ...